Subcutaneous Ocrelizumab, Ofatumumab 'Reassuring' in MS : vi

Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.

Related Keywords

Baltimore , Maryland , United States , Nevada , Johns Hopkins University , Milan , Lombardia , Italy , Bristol Myers Squibb , Leh Hua , Scottd Newsome , Las Vegas , Bristol Meyers Squibb , Julie Fiol , Lundbeck , Roche Ltd , Us National Ms Society , Serono , Brain Health , National Ms Society , Stiff Person Syndrome Center , Research In Multiple Sclerosis , Stiff Person Syndrome Research Foundation , Novartis , Patient Centered Outcomes Research Institute , Department Of Defense , Cleveland Clinic Lou Ruvo Center , Americas Committee For Treatment , European Committee For Treatment , Genentech , Joint European Committee , Multiple Sclerosis , Americas Committee , Expanded Disability Status Scale , Clinical Innovation , Medscape Medical , Greenwich Biosciences , Horizon Therapeutics , Patient Centered Outcomes Research , Multiple Sclerosis Americas Committee , Multiple Sclerosis Ms , Us , Monoclonal Antibody , Etuximab , Ituximab , Clinical Research , Clinical Trials , Linical Studies , Intravenous Iv , Intravenous , Tv , Biologic Therapy , Europe , European , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Stiff Person Syndrome , Eigg , Brain , Medical Innovations , Nnovations In Medicine , Primary Progressive Multipl ,